StandardX Raises £10M Seed to Build Scalable Isotope Refinery

StandardX, a UK-headquartered deep-tech company, has raised £10 million in Seed funding. The round was led by Vsquared Ventures, with participation from Firstminute Capital, Brevan Howard Macro Venture Fund, Geometry, UKI2S, and East X Ventures. The funding date is September 23, 2026.

What StandardX Does

StandardX is building what it describes as the world's first scalable isotope refinery. At the core of the company is a proprietary compact accelerator system designed to manufacture the full portfolio of rare isotopes at commercial scale on a standard industrial footprint. The approach aims to replace today's fragmented, isotope-specific production infrastructure with a single, scalable platform.

Founded in 2025 by nuclear engineers Richard Pearson and Ross Allen, StandardX is initially targeting isotopes for cancer diagnosis and treatment, including targeted alpha therapies. The company also plans to extend the same platform to tritium fuel for fusion energy under signed agreements with fusion developers.

Roadmap and Milestones

According to the company, StandardX aims to supply its first isotopes to a medical research partner in 2027 and reach industrial-scale production from 2029. These milestones frame the company's near-term commercial path: first, validating its isotope output with a medical research partner, then scaling toward industrial production volumes.

Why This Matters for Acquisition Watchers

StandardX sits at the intersection of two long-term demand drivers: advanced medical isotopes for cancer diagnosis and treatment, and tritium fuel for fusion energy. The company's proposition is not a single isotope product but a platform capable of producing a broad portfolio of rare isotopes. If the compact accelerator system performs as intended, it could reduce reliance on fragmented, isotope-specific production infrastructure.

For strategic acquirers in nuclear technology, medical isotopes, or fusion energy supply chains, StandardX represents an early-stage but platform-oriented asset. The Seed round provides capital to advance from founding in 2025 toward first isotope supply in 2027 and industrial-scale production from 2029.

Round Details

Company: StandardX
Headquarters: United Kingdom
Founded: 2025
Founders: Richard Pearson and Ross Allen
Round: Seed
Amount: £10,000,000
Funding date: September 23, 2026
Lead investor: Vsquared Ventures
Participating investors: Firstminute Capital, Brevan Howard Macro Venture Fund, Vsquared Ventures, Geometry, UKI2S, East X Ventures

The Technology Platform

StandardX's compact accelerator system is described as proprietary and designed for a standard industrial footprint. The company's stated goal is commercial-scale manufacturing of the full portfolio of rare isotopes. Its initial focus is cancer diagnosis and treatment isotopes, including targeted alpha therapies. The same platform is intended to extend to tritium fuel for fusion energy under signed agreements with fusion developers.

What to Watch

Progress toward supplying first isotopes to a medical research partner in 2027.
Execution on the path to industrial-scale production from 2029.
Expansion of the platform from medical isotopes to tritium fuel for fusion energy.
Deployment of the Seed capital against the compact accelerator system and refinery build-out.

StandardX's Seed round, led by Vsquared Ventures and backed by a syndicate including Firstminute Capital, Brevan Howard Macro Venture Fund, Geometry, UKI2S, and East X Ventures, positions the company to pursue its stated milestones in medical isotopes and fusion fuel.